FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer

Drug

Datroway (datopotamab deruxtecan-dlnk) · Anti-TROP2 antibody-drug conjugate

Condition

Breast